Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) EBIT: ﷼306 Mil (TTM As of Mar. 2026)


SAU:2070 Saudi Pharmaceutical Industries & Medical Appliances Corp SAU:2070
73 GF Score
Price ﷼28.58
GF Value ﷼31.13
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Saudi Pharmaceutical Industries & Medical Appliances EBIT?

Saudi Pharmaceutical Industries & Medical Appliances SAU:2070 -0.90% 73 EBIT is ﷼306 Mil as of Mar. 2026. GuruFocus rates SAU:2070 with a GF Score™ of 73/100 and a GF Value™ of ﷼31.13 (Fairly Valued). The stock has 6 warning signs investors should review.

Saudi Pharmaceutical Industries & Medical Appliances's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ﷼98 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ﷼306 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Saudi Pharmaceutical Industries & Medical Appliances's annualized ROC % for the quarter that ended in Mar. 2026 was 11.02%. Saudi Pharmaceutical Industries & Medical Appliances's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Saudi Pharmaceutical Industries & Medical Appliances's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.79%.

Saudi Pharmaceutical Industries & Medical Appliances  (SAU:2070) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Saudi Pharmaceutical Industries & Medical Appliances's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=412.84 * ( 1 - 12.42% )/( (3329.42 + 3235.055)/ 2 )
=361.565272/3282.2375
=11.02 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4367.751 - 653.949 - ( 384.382 - max(0, 1859.857 - 2376.136+384.382))
=3329.42

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4270.413 - 693.754 - ( 341.604 - max(0, 1820.148 - 2291.006+341.604))
=3235.055

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Saudi Pharmaceutical Industries & Medical Appliances's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=390/( ( (1753.133 + max(1067.363, 0)) + (1767.535 + max(1017.631, 0)) )/ 2 )
=390/( ( 2820.496 + 2785.166 )/ 2 )
=390/2802.831
=13.91 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1176.435 + 611.029 + 172.58) - (653.949 + 0 + 238.732)
=1067.363

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1192.494 + 587.569 + 132.322) - (693.754 + 0 + 201)
=1017.631

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Saudi Pharmaceutical Industries & Medical Appliances's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=306.235/4511.476
=6.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Saudi Pharmaceutical Industries & Medical Appliances EBIT Related Terms

Saudi Pharmaceutical Industries & Medical Appliances EBIT Historical Data

* Premium members only.

The historical data trend for Saudi Pharmaceutical Industries & Medical Appliances's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Saudi Pharmaceutical Industries & Medical Appliances EBIT Chart

Saudi Pharmaceutical Industries & Medical Appliances Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.13 -98.25 79.56 167.85 303.79

Saudi Pharmaceutical Industries & Medical Appliances Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.06 72.75 73.35 62.64 97.50

SAU:2070 vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Saudi Pharmaceutical Industries & Medical Appliances's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Saudi Pharmaceutical Industries & Medical Appliances EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Saudi Pharmaceutical Industries & Medical Appliances's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Saudi Pharmaceutical Industries & Medical Appliances's EV-to-EBIT falls into.


SAU:2070
73GF Score
Saudi Pharmaceutical Industries & Medical Appliances Corp SAU:2070
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Saudi Pharmaceutical Industries & Medical Appliances EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼306 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ﷼306 Mil mean?
Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) has a EBIT of ﷼306 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Saudi Pharmaceutical Industries & Medical Appliances.
Is Saudi Pharmaceutical Industries & Medical Appliances' EBIT too high?
Saudi Pharmaceutical Industries & Medical Appliances' current EBIT is ﷼306 Mil. Overall, Saudi Pharmaceutical Industries & Medical Appliances has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Saudi Pharmaceutical Industries & Medical Appliances' EBIT compare to ZTS and UTHR?
Saudi Pharmaceutical Industries & Medical Appliances' EBIT of ﷼306 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Saudi Pharmaceutical Industries & Medical Appliances. Saudi Pharmaceutical Industries & Medical Appliances's current EBIT is ﷼306 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saudi Pharmaceutical Industries & Medical Appliances stock overvalued right now?
Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) is currently considered Fairly Valued. The stock's GF Value™ is ﷼31.13, compared to a current price of ﷼28.58 — trading 8.2% below its estimated fair value. The current EBIT is ﷼306 Mil. Saudi Pharmaceutical Industries & Medical Appliances' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070), the current EBIT is ﷼306 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) Overvalued in 2026?

Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances stock appears to be undervalued. The current stock price of ﷼28.58 is trading 8.2% below its estimated GF Value™ of ﷼31.13. GuruFocus considers Saudi Pharmaceutical Industries & Medical Appliances to be Fairly Valued.

Key valuation signals for SAU:2070:

  • EBIT: ﷼306 Mil
  • GF Value™: ﷼31.13 vs. price of ﷼28.58 (8.2% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the SAU:2070 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Saudi Pharmaceutical Industries & Medical Appliances Business Description

Address King Abdul Aziz Road, Industrial City of Al-Qassim, Buraidah, SAU
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. The segments of the company are Pharmaceutical Manufacturing, Trading and Distribution services, and Healthcare Services, out of which the company derives maximum revenue from the Pharmaceutical Manufacturing segment. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco, and Algeria.
73GF Score

Get the complete analysis for SAU:2070

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

﷼28.58
Price
﷼31.13
GF Value